Inhibrx Biosciences (INBX) Asset Utilization Ratio (2024 - 2025)
Inhibrx Biosciences' (INBX) quarterly Asset Utilization Ratio came in at 0.01 in Q4 2025, down 4.96% year-on-year from 0.01 in Q4 2024, and up 20.26% on a QoQ basis from 0.01 in Q3 2025.
Inhibrx Biosciences (INBX) Asset Utilization Ratio (2024 - 2025) Analysis & Trends
Inhibrx Biosciences (INBX) has 2 years of Asset Utilization Ratio data on file, last reported at 0.01 in Q4 2025.
- On a quarterly basis, Asset Utilization Ratio fell 4.96% year-over-year to 0.01 in Q4 2025; TTM through Dec 2025 was 0.01, a 4.96% decrease from a year earlier, with the FY2025 full-year figure at 0.01, up 870.62% from the prior year.
- Asset Utilization Ratio for Q4 2025 stood at 0.01, up from 0.01 in the prior quarter.
- Over the last five years, Asset Utilization Ratio for INBX reached as high as 0.01 in Q4 2024 and fell as low as 0.01 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.69 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 0.47 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.37 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Inhibrx Biosciences | 1.32 Bn | 1.32 Bn | - | 0.01 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.01 |
| Sep 30, 2025 | 0.01 |
| Jun 30, 2025 | 0.01 |
| Dec 31, 2024 | 0.01 |
| Sep 30, 2024 | 0.01 |